About
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) — investor relations, events, news, and company updates on 6ix.
Latest News
Sep 12 2022
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
May 18 2022
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
May 16 2022
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
Mar 1 2022
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
Feb 16 2022
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
Financials
Revenue
$0
Market Cap
$15.23 B
EPS
-0.01
Translate